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Cardiopulmonary b pass results in a "euthyroid sick" state. Recently, interest has 
focused on the relationship between low serum triiodothyronine levels and postoperative 
cardiovascular hemodynamics. The present study was undertaken tomore clearly define 
the acute efects of triiodothyronine on myocardial mechanics and energetics after 
hypothermic global ischemia using an ex-vivo canine heart preparation to model the 
clinical condition. Experiments were performed on isolated hearts subjected to hy- 
perkalemic arrest with 90 minutes of hypothermic (10 ° C) ischemia. Isolated hearts were 
cross-perfused by euthyroid support dogs in which triiodothyronine levels spontane- 
ously decreased by 65% to 75% (p < 0.01) after the initiation of cross-perfusion. I  nine 
heart preparations, triiodothyronine (Triostat) was given as a bolns dose (0.2 tig/kg) 
after 1 hour of baseline data collection with a subsequent measurable rise in serum 
triiodothyronine levels (p < 0.01). In six postischemic hearts, reverse triiodothyronine 
was given as a 0.2 pg/kg bolus. Triiodothyronine was also administered toa group of 
eight nonischemic, ontinuously perfused isolated hearts. Intrinsic myocardial contrac- 
tility was assessed by analysis of the preload reeruitable stroke work area, energetic 
efliciency from the myocardial oxygen consumption-pressure-volnme area relationship, 
and coronary vascular resistance from analysis of coronary flow and perfusion pressure. 
Acute administration oftriiodothyronine to postischemic hearts improved the preload 
recruitable stroke work area from 9.5 - 1.42 to 14.9 -/-- 2.03 x 107 erg/tal, a 56% increase 
t~om baseline (p < 0.001), but had no effect on the preload recruitable stroke work area 
of the nonischemic hearts. The inotropic response resulting from triiodothyronine 
treatment did not alter the myocardial oxygen consumption-pressure-volume area 
relationship. Triiodothyronine treatment was associated with significantly decreased 
coronary resistance and increased coronary flow through a range of diastolic loading 
conditions in the postischemic hearts. The biologically inactive thyroid hormone 
metabolite reverse triiodothyronine was without effect on any of the measured param- 
eters. On the basis of these resuits, we conclude that the low triiodothyronine state of 
cardiopulmonary b pass can be reproduced in this isolated heart model and that acute 
triiodothyronine treatment results in a unique inotropic action manifest only in the 
postischemic reperfused myocardium and is accomplished without oxygen wasting 
effects. (J THORAC CARDIOVASC SURG 1995;109:457-65) 
John D. Klemperer, MD, a John Zelano, PhD, a Robert E. Helm, MD, a 
Karen Berman, BS, a Kaie Ojamaa, PhD, b Irwin Klein, MD, b O. Wayne lsom, MD, a and 
Karl Krieger, MD, a New York and Manhasset, N.Y. 
T hyroid hormone has profound effects on the heart and cardiovascular system. TM Although the 
sequelae of chronic hyperthyroid and hypothyroid 
states are weil documented, the effects of acute 
alterations in serum hormone levels have been less 
thoroughly characterized. Cardiopulmonary bypass 
(CPB) results in a "euthyroid sick" state, 5'6 and 
interest has focused on the relationship between low 
serum triiodothyronine (T3) levels and postopera- 
tive cardiovascular hemodynamics. Accumulating 
experimental data suggest hat pharmacologic T 3 
supplementation may improve hemodynamic pa- 
rameters after ischemic injury in animal models of 
CPB 7-9 and in isolated heart studies. 1°' 11 Limited 
clinical data also suggest a benefit o short-term T3 
supplementation in the peri-CPB period. 12' 13 The 
mechanism of action of T 3 in these settings remains 
uncharacterized, yet the rapid improvement in left 
ventricular function reveals the importance of ex- 
tranuclear pathways. Because thyroid hormones are 
known to affect systemic vascular resistance, 14' is 
direct cardiac effects of T3 are best measured with 
load-independent parameters of ventricular func- 
tion. Published reports in which isolate heart models 
were used, however, have relied on severe warm 
ischemic injury and crystalloid perfusates and have 
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Fig. 1. Experimental protocol. The stages of the experiment are outlined with corresponding time 
intervals listed. Two data sets were collected uring the baseline period and three during the posttreatment 
period. 
not addressed the left ventricular pressure-volume 
area-oxygen consumption (PVA-MVO2) relation- 
ship. The present study was undertaken to delineate 
the acute effects of T 3 on myocardial mechanics and 
energetics after hypothermic global ischemia with a 
canine ex vivo isolated heart model used to mimic 
the clinical condition. 
Methods 
Operative procedures. All animals received humane 
care in complianee with the "Principles of Laboratory 
Animal Care" formulated by the National Society for 
Medical Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the National Academy 
of Sciences and published by the National Institutes of 
Health (NIH Publication No. 86-23, revised 1985). 
Individual experiments involved the use of two adult 
mongrel dogs as previously described. 16 In each experi- 
ment, the heart of one animal was used as the ex vivo 
isolated heart preparation that was cross-perfused by the 
second dog as the support animal. The animals were 
allowed food and water ad libitum the night before the 
experiments o avoid acute alteration of thyroid hormone 
levels. Animals were sedated with acepromazine (0.1 
mg/kg intramnscularly) and anesthesia was induced with 
pentobarbital (25 to 30 mg/kg intravenously) and main- 
tained with isoflurane (0.4% to 1.5%). The animals were 
intubated and ventilated by a mechanical respirator. Ce- 
fazolin (Kefzol, 1 gm intravenously) and indomethacin 
(50 mg by suppository) was given to each support animal 
at the onset of surgical intervention. The electrocardio- 
gram and mean arterial blood pressure were continuously 
monitored. 
Support änimal and cross-circulation. An 8F catheter 
was placed in the left femoral vein for fluid and drug 
administration. The animal was fully heparinized (400 
U/kg intravenous bolus, followed by a continuous infusion 
of 500 U/hr). The circuit has been deseribed in detail in an 16 earlier report. In brief, the right femoral vessels were 
cannulated with 18F cannulas (Bard Vascular Systems, 
Billerica, Mass.) and conneeted to the circuit with 3/~-inch 
tubing. A double roller head pump (Masterflex/Cole- 
Parmer Instrument Co., Chicago, Ill.) was used to pump 
bidirectional flows of arterial and venous blood in syn- 
chronous flow rates, which were controlled by a custom 
servo deviee to maintain constant coronary perfusion 
pressure (70 to 80 mm Hg) to the ex vivo heart. The circuit 
required a prime volume of 500 ml crystalloid solution 
before it was connected to the support animal. Hemody- 
namic stability was maintained by the infusion of fluids 
(crystalloid and dextran) when needed. Arterial pH was 
maintained within normal range by adjustment of the 
ventilator tidal volume and rate or the administration of 
sodium bicarbonate. Arterial inflow into the ex vivo 
heart's aorta and coronary sinus drainage were simulta- 
neously measured by ultrasonic flow probe s (Transonic, 
Ithiea, N.Y.). 
Ex vivo heart preparation/hypothermic ischemia model. 
Through a sternotomy incision, a pericardial cradle was 
created. The great vessels were isolated and surrounded 
by sutures or tapes. After heparinization, the subclavian 
artery was cannulated with a catheter for monitoring of 
coronary perfusion pressure. The venae eavae and bra- 
chiocephalic artery were tied, followed by crossclamping 
of the descending aorta and ligation of the main pulmo- 
nary artery. Cardioplegic arrest was achieved by infusion 
of cold hyperkalemic rystalloid solution (750 ml of 
Normosol with 20 mEq potassium chloride, 5 ° C, adjusted 
to pH 7.5) into the previously placed subclavian arterial 
tubing. The heart was then excised and placed in 10 ° C 
Normosol solution. 
During the 90-minute hypothermic arrest period, the 
heart was prepared for the ex vivo circuit. The brachioce- 
phalic artery was cannulated for retrograde coronary 
perfusion and the right ventricle for coronary sinus drain- 
age. A plastic O ring was sutured to the mitral anulus for 
mounting to the servo pump. 
After 90 minutes of hypothermic ischemia, the heart 
was cleared of air in a basin of warm Normosol solution 
and reperfusion was begun at 40 mm Hg for the initial 10 
minutes, then increased to 70 to 80 mm Hg for the 
remainder of the experiment. After being mounted on the 
servo apparatus, the left ventricular balloon was secured 
through an apical stab wound. Epicardial pacing wires 
were placed and pacing was maintained at 150 beats/min 
(Grass Instrument Co., Quincy, Mass.). The temperature 
of the blood in the circuit was maintained at 37 ° C by a 
heat exchanger. 
Experimental protocol. An outline of the experimental 
protocol is shown in Fig. 1. The postischemic hearts were 
reperfused with warm oxygenated blood from the support 
animal for 30 minutes before baseline data eolleetion 
was begun. Data collection through a range of diastolic 
loading conditions was pefformed in 30-minute intervals. 
In nine heart preparations, T3 (Triostat, SmithKline 
Beecham Pharmaceuticals, Philadelphia, Pa.) was given as 
a 0.2/zg/kg bolus after 1 hour of baseline data collection. 
A 30-minute quilibration period was then allowed before 
resuming data eollection every 30 minutes for a total 
period of 90 minutes. A second group of animals (n = 6) 
received reverse T3 (rT3, Sigma Chemical Co., St. Louis, 
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Mo.) as a 0.2/xg/kg bolus dose and similar measurements 
were taken. 
The isolated heart preparation, a modification of the 
method of Sagawa nd coworkers, 17 uses a computerized 
servo pump equipped with a mock circulatory system to 
collect a set of pressure-volume loops under a constant 
afterload and a range of increasing diastolic filling pres- 
sures set by the investigator. The left ventricular pressure, 
left ventricular volume, coronary perfusion pressure, and 
coronary sinus outflow were measured simultaneously and 
collected at 250 Hz by custom data software. Blood 
samples were collected at the same time for determination 
of the MVO2. The heart was allowed to equilibrate for 3 
to 5 minutes at each preload setting before data collec- 
tion. A minimum of four loading conditions was measured 
for each data set. 
Blood was taken for measurement of serum T 3 levels 
during placement of intravenous lines (baseline) from 
both support and donor animals. Support animals had 
subsequent blood withdrawal via the circuit at the end of 
baseline data collection and then 1 hour after drug 
administration. Whole blood was centrifuged and the 
serum was stored at -5  ° C. Hormone levels were deter- 
mined by radioimmunoassay t a commercial animal 
laboratory (Animal Medical Center, New York, N.Y.). 
Measurement of parameters 
Analysis of lefi ventricular function and PVA. The left 
ventricular performance was derived from analysis of the 
stroke work/end-diastolic volume relationship, which 
yielded an x intercept, slope, and the preload recruitable 
stroke work area (PRSWA) extrapolated to an end- 
diastolic volume of 100 m118 at each data interval. 
Total mechanical energy production was measured as 
the PVA for each preloading condition with the use of 
custom software modeled after the method of Sagawa nd 
eolleagues. ~9These PVAs are plotted against he corre- 
sponding MVO2 values to generate the PVA-MVO2 
relationship. 
MVO2. Aortic and coronary sinus oxygen tension (Po2), 
oxygen saturation, and hemoglobin (HGB) were measured 
by a blood gas/pH analyzer and a Co-Ox/meter device 
(Instrumentation Laboratory Inc., Lexington, Mass.). 
MVO 2 per cardiac ycle was calculated as ([Cao 2 - Cv02] 
× coronary flow)/wet left ventricular weight × heart rate. 
Caoa and Cvoa denote arterial and venous oxygen content, 
respectively. Oxygen eontent was calculated as (1.38 × 
Hgb × percent saturation of Hgb) + (0.003 × Po2). 
MVO2 in milliliters of oxygen per 100 gm. beat was 
converted into mm Hg. ml/100 gin. beat by multiplying 20 
joules/ml of oxygen and 7502 mm Hg. ml/joule. 
Coronary resistance. The resistive component (mm 
Hg-min/ml) of the coronary vascular impedance was 
calculated as the mean coronary perfusion pressure di- 
vided by the mean coronary flow after 3 to 5 minutes of 
equilibration at each diastolic loading condition. 
Diastolic constant. Diastolic function is expressed in 
terms of the diastolic stiffness constant (ko) of the expo- 
nential equation describing the end-diastolic pressure- 
volume relationship P = be kv, where P and V represent 
end-diastolic pressure and volume, respectively, and b is 
the left ventricular pressure extrapolated to zero vol- 
ume.  2o 
Statistical methods. All values are expressed as the 
mean plus and minus the standard error. For each indi- 
vidual experiment, the two baseline data sets were aver- 
aged as were the three posttreatment data sets. Baseline 
data were then pooled for statistical comparison to pooled 
posttreatment data. Comparisons within and between 
experimental groups were performed with paired and 
two-sample t tests, respectively. Coronary resistance and 
flow data were analyzed by analysis of variance with 
repeated measures. A p value of less than 0.05 was 
considered statistically significant. 
Results 
T 3 levels. Total serum T3 levels were normal in 
both donor and support animals at the onset of the 
experiment. After the initiation of cross-perfusion, 
mean serum T3 levels in the support animals de- 
creased from 0.55 2 0.07 to 0.13 + 0.01/xg/dl (p < 
0.01). This decrease was associated with an average 
drop in hemoglobin value from 13 to 9.8 gin/dl. 
Mean T 3 levels subsequently rose to 0.58 2 0.05 
/xg/dl (p < 0.01) 60 minutes after the T 3 bolus. In the 
experiments in which rT 3 was used, serum T 3 levels 
dropped to a mean value of 0.10 +_ 0.01 ~g/dl (p < 
0.01) and did not rise after the rT 3 bolus. 
Contractility. The changes in intrinsic myocardial 
contractility were evaluated by analysis of the 
PRSWA before and after T3 or rT 3 administration. 
Data collected during the pre-T 3 period (baseline) 
were pooled, as were the post-T 3 data (Fig. 2). 
Administration of T 3 to postischemic hearts im- 
proved the PRSWA from 9.5 + 1.42 to 14.9 + 2.03 
× 107 erg/tal, a 56% increase over baseline that was 
highly significant (p < 0.001). Administration of the 
biologically inactive metabolite rT 3 did not change 
contractility compared with baseline (8.82 + 1.40 to 
8.16 +_ 1.31 × 107 erg/tal). The hearts treated with 
T 3 and rT 3 in this set of experiments did not differ 
significantly at baseline with respect to PRSWA. 
Prior analysis of a group of untreated postischemic 
as well as continuously perfused, nonischemic hearts 
revealed no significant change in PRSWA over a 
3-hour time period (manuscript in preparation). 
Administration of T 3 to the nonischemic, normal 
hearts was without significant effect on contractility 
(9.79 + 1.15 to 8.42 +_ 0.97 × 107 erg/ml). 
PVA-MVO2. Data from each experiment were 
analyzed individually and then pooled for statistical 
analysis of the PVA-MVO 2 relationship. Fig. 3, A 
and B shows the linear regressions for each experi- 
mental group as labeled. The two groups did not 
differ significantly from each other at baseline. A1- 
though T 3 treatment was associated with a pro- 
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Fig. 2. Effect of T 3 and rT  3 on  intrinsic myocardial contractility. All values are expressed as the mean + 
the standard error of the mean. */7 < 0.001 versus pre T 3 by paired t test and versus pre and post rT3 by 
two-sample t test. 
nounced inotropic effect, the PVA-MVOz relation- 
ship was not significantly altered. The y intercepts 
were 4414 and 4411 mm Hg. tal/100 gin. beat and 
the slopes 2.45 and 2.58 before and after T 3 treat- 
ment. No significant changes in the y intercept or 
slope occurred after rT3 bolus. 
Diastolic function. Left ventricular diastolic func- 
tion was expressed as the diastolic stiffness constant 
(kp), as derived from the exponential equation P = 
be kv describing the left ventricular end-diastolic 
pressure-volume r lationship (Table I). Although 
compliance decreased in both groups, neither 
change was statistically significant. 
Coronary vascular responses. The coronary vas- 
cular resistance was calculated from the aortic root 
or coronary perfusion pressure divided by the coro- 
nary flow measured after 3 to 5 minutes of equili- 
bration through a range of diastolic loading condi- 
tions (Table II). These were arbitrary settings 
corresponding to end-diastolic ventricular pressures 
in the range of 4 to 20 mm Hg. T 3 significantly 
reduced coronary resistance throughout the range 
of loading conditions in the ischemic reperfused 
hearts. This reduction in coronary vascular esis- 
tance in the T3-treated hearts resulted in a signifi- 
cant increase in blood flow at each diastolic pressure 
setting, as shown in Table III. rT 3 did not alter 
coronary vascular esistance or flow rate. 
Discussion 
Recently, interest has focused on the effects of an 
acute deficiency of circulating total and free T 3 
arising as a consequence of CPB 5' 6, zl on postoper- 
ative cardiac performance. Several studies have 
suggested that T 3 repletion in this setting has hemo- 
dynamic benefits. Novitzky and colleagues reported 
an improvement in postischemic left ventricular 
function after experimental CPB and cardioplegic 
arrest in pigs 7 and dogs that had received T3 after 
removal of the aortic crossclamp. These studies, 
however, used load-dependent parameters of ven- 
tricular function that do not accurately reflect pri- 
mary cardiac effects. Dyke and associates, 11 using an 
isolated rabbit heart model, found that T 3 treatment 
administered immediately atthe time of reperfusion 
restored peak developed pressure after ischemia. A
more recent report from this group describes im- 
proved load-independent ventricular function (using 
the stroke work-end-diastolic volume relationship) 
in response to T 3 treatment in an experimental 
model of CPB. 9 Both studies, however, involved 
severe warm ischemic injury and did not investigate 
the relationship between cardiac work and MVO2. 
The goal of this study was to characterize the 
effects of T 3 administered immediately on load- 
independent parameters of left ventricular function 
and on myocardial energetics in a model of hypo- 
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Fig. 3. Effect of T 3 (A)  and rT  3 (B) on the PVA-MVO 2 relationship n postischemic hearts. Straight lines 
represent the linear regressions of the data sets as labeled. 
thermic global ischemia designed to mimic the 
clinical situation encountered in the peri-CPB or 
transplantation period. The ex vivo isolated heart 
preparation eliminates variability in left ventricular 
loading conditions and establishes a hormonal envi- 
ronment hat approximates clinical CPB. 
The observed 65% to 75% drop in the total serum 
T 3 levels of the support animals correlates with 
clinical experience, s' 6 Although the mechanism un- 
Table I. Left ventricular function: diastolic stiffness 
constant (Ic)* 
After 
Baseline treatment 
Post ischemic  + T3 0.068 _+ 0.009 0.090 +_ 0.021 
Post ischemic + rT3 0.058 _+ 0.007 0.097 _+ 0.023 
All values are mean _+ standard error of the mean. 
*Derived from the equation P = be k~ describing the end-diastolic pres- 
sure-volume relationship. 
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Table Il. Coronary vascular esistance 
Diastolic loading conditions* 
5 15 25 35 
Postischemic 
Baseline 0.733 _+ 0.067 0.681 + 0.06 0.575 _+ 0.05 0.538 -+ 0.04 
Post T 3 0.581 _+ 0.035? 0.507 + 0.035? 0.464 _+ 0.0305 0.421 -+ 0.027? 
Postischemic 
Baseline 0.703 _+ 0.152 0.614 _+ 0.04 0.563 + 0.065 0.509 _+ 0.058 
Post rT~ 0.674 + 0.115 0.601 -+ 0.096 0.553 + 0.073 0.491 -+ 0.064 
Coronary resistance expressed inmeans -+ standard error of the mean (mm Hg. min/tal) for four diastolic loading conditions. 
*Arbitrary loading conditions corresponding toend-diastolic pressures ranging from 4 to 20 mm Hg. 
tp < 0.05 versus corresponding baseline values by analysis of variance. 
:~p = 0.06 versus corresponding baseline values by analysis of variance. 
derlying this decrease was not addressed, it could 
not be completely attributed to the hemodilution 
related to the preparation. An acute stress response 
resulting from the inherent rauma of extracorpo- 
real circulation and the added work imposed by the 
ex vivo heart on the support dog may have contrib- 
uted to the low T 3 state in this model as a result of 
decreased peripheral conversion of thyroxine (T4) to 
T3, shortened half-life of T 3, and/or altered volume 
of distribution for the hormone. 
Our isolated heart preparation is similar to pre- 
viously described animal models of hyperkalemic 
cardioplegic arrest followed by a period of global, 
hypothermic ischemia in which systolic function is 
preserved. 22-24 However, whether T3 could affect he 
performance of hearts subjected to a period of 
protected hypothermie schemia followed by reper- 
fusion has not been tested in a setting where loading 
conditions are carefully controlled. 
In the present study, 3"3 treatment resulted in a 
56% increase in PRSWA in the postischemic hearts. 
In agreement with an earlier report, 11 no inotropic 
response to T3 was observed in the nonischemic, 
continuously perfused hearts. Similar to the myocar- 
dium injured by normothermic ischemia, TM T 3 aug- 
mented ventricular performance in the hypothermic 
arrested myocardium. This is consistent with data 
reported by Novitzky and associates, 7 in which T 3 
treatment in a porcine model of CPB, with pro- 
tected cardioplegic arrest, resulted in a peak devel- 
oped pressure greater than baseline. The PRSWA is 
an index of intrinsic myocardial contractility inde- 
pendent of loading conditions and is recognized as 
a more sensitive measure of ventricular perfor- 
mance.25,  26 
Orte emphasis of this study was to eharacterize the 
effects of T3 on myocardial energetics in terms of 
efficiency, namely, the ratio of total mechanical 
energy production to total myocardial energy con- 
sumption. The linearity of the PVA-MVO 2 relation- 
ship has been well described. 27The slope of this 
regression is inversely proportional to the efficiency 
of energy use, and the extrapolated y intercept 
represents he energy requirement of the unloaded 
contracting ventricle. Traditional /3-agonist inotro- 
pic agents such as dobutamine 16' 21 and epineph- 
rine 28 shift the PVA-MVO 2 regression line upward. 
This elevation of the y intercept represents an 
"oxygen wasting effect" in which an increased 
amount of energy is required in the enhanced state 
compared with the normal stare for the same level of 
total work. T3, in the dose of 0.2 tzg/kg, restored 
serum T 3 to physiologic levels and produced a 
significant inotropic effect without incurring addi- 
tional oxygen debt. The PVA-MVO 2 relationship 
was similar before and after T 3 administration. The 
PVA-MVO 2 relationship was unaffected by rT 3 
treatment, which showed no inotropic effect. Con- 
flicting, though perhaps species-dependent, de- 
scriptions of the PVA-MVO2 relationship in the 
chronically hyperthyroid left ventricle have been 
reported.29, 3oThe acute effects of T3 treatment in a 
hormonally depleted environment represent a fun- 
damentally different situation, and this report is the 
first to directly characterize myocardial energetics in
this setting. 
One effect of thyroid hormones is a decrease in 
peripheral vascular esistance. 14' 15 Recent studies 
suggest hat T 3 may act as a direct vasodilator on 
arterial smooth muscle cells, 15' 31 yet its influence on 
coronary arterial tone has not been established. Our 
data suggest that T3 may substantially increase 
blood flow to the coronary bed. Coronary resistance 
is determined by perfusion pressure and flow. Flow 
is most dependent on the demand of the myocar- 
dium, which is strongly influenced by the loading 
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Table III. Coronary flow 
Diastolic loading conditions* 
5 15 25 35 
Postischemic 
Baseline 109 + 9.6 115.6 -+ 8.9 136.9 +_ 11.1 150.2 + 11.3 
Post T 3 140.7 + 14.5t 167.3 _+ 17t 181.4 _+ 17.3t 198.4 _+, 14.2"~ 
Postischemic 
Baseline 120 + 17.2 131.4 _+ 17.6 141.7 _+ 15.7 157.4 + 15.6 
Post rT3 126 -+ 17.3 135.6 + 18 147.4 _+ 18.2 163.5 +_ 21,4 
Coronary flow expressed in means _+ standard error of the mean (ml/min) for four diastolic loading conditions. 
*Arbitrary loading conditions corresponding toend-diastolic pressures ranging from 4 to 20 mm Hg. 
tp < 0.05 versus corresponding baseline values by analysis of variance. 
conditions and contractile activity of the heart. The 
isolated heart model, in which coronary perfusion 
pressure and afterload can be kept constant, is weil 
suited for examining changes in vascular tone. Al- 
though it is ditficult o distinguish a primary vasodi- 
latory effect from a response to the enhanced con- 
tractile state, the finding that the augmentation of
contractility occurred without additional oxygen re- 
quirement supports such an effect. Kadletz and 
coworkers 32 have recently reported that T 3 did not 
increase coronary flow in a rat heart Langendorff 
preparation i volving warm ischemia. Several differ- 
ences in method may account for the discrepancy. 
The two models differ in type of injury, perfusate, 
and sampling time relative to reperfusion. We have 
noted that during the initial period of reperfusion, 
the postischemic hearts are markedly hyperemic. If
data collection is obtained before a sufficient inter- 
val of stabilization after reperfusion is completed, it 
is possible that an already dilated coronary vascula- 
ture may not be additionally influenced by T 3 ad- 
ministration. 
Although the present model does not provide a 
molecular basis for the effects of T 3 on  left ventric- 
ular function, the rapidity of onset of the effect 
suggests an extranuclear mechanism. Despite inten- 
sive investigation into the interaction with several 
cell membrane and enzyme systems, 33 the mecha- 
nism(s) responsible for the acute action of T 3 are 
not well defined. The inotropic action of T 3 on the 
postischemic myocardium ay relate to alterations 
in intracellular and transcellular calcium handling 
after injury. Ischemia-reperfusion may result in pro- 
found disturbances in intracellular calcium 34 and 
sodium 35 balance, along with depression of key 
enzyme systems uch as calcium adenosinetriphos- 
phatase in the sarcoplasmic ret icu lum.  36'37 The 
known effects of T 3 on  myocardial calcium han- 
dling 3s-4° and sodium channel activity 41 suggest po- 
tential routes through which the postischemic myo- 
cardium may be acutely responsive to T3 treatment. 
Although T 3 is known to affect left ventricular 
diastolic function, 2'42 we did not observe significant 
change after T3 administration. This analysis, how- 
ever, did not measure the rate of diastolic relax- 
ation. 
Some interesting comparisons between T 3 and 
bipyridine phosphodiesterase inhibitors can be 
made. At a biochemical level, T 3 and milrinone were 
reported to display structural and functional homol- 
ogies. 43 In addition, the relationship between ino- 
tropic effect and oxygen utilization etficiency ob- 
served with T 3 is similar to that reported for 
amrinoneJ 6 Finally, Caldarone and associates 44
have described an inotropic specificity of milrinone 
for the postischemic reperfused heart with no effect 
on normal hearts. 
In summary, the ex vivo isolated heart prepara- 
tion cross-circulated bya support dog was found to 
be a useful model for evaluating the effects of acute 
T 3 administration i a hormonal environment that 
mimics the clinical condition of CPB. Specificity for 
the postischemic myocardium has been suggested by 
earlier experimental literature, and, despite preser- 
vation of left ventricular contractility in our model, 
the ischemic interval followed by reperfusion al- 
lowed an inotropic effect of T 3 to be manifest. This 
report is the first to characterize the acute effects of 
T 3 on the postischemic heart with respect o the 
PVA-MVO2 relationship and clearly shows that T 3 
augmentation of postischemic left ventricular func- 
tion occurs without oxygen wasting effects. In addi- 
tion, T 3 appears to have a vasodilatory effect on the 
coronary vasculature. Together, these findings lend 
additional support for repleting T 3 levels in the 
setting of myocardial ischemia-reperfusion. 
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